Health Enhancement Products, Inc. Sponsors Research at Arizona Center for Algae Technology & Innovation & ATP3 to Facilitate ...
November 12 2013 - 10:30AM
Marketwired
Health Enhancement Products, Inc. Sponsors Research at Arizona
Center for Algae Technology and Innovation and ATP3 to Facilitate
Bioactives Commercial Production
BLOOMFIELD HILLS, MI--(Marketwired - Nov 12, 2013) -
Health Enhancement Products, Inc. (OTCBB: HEPI), which
investigates and licenses algae-derived, high-value bioactive
molecules that benefit human and animal health, has formalized a
one-year sponsored research project with the Arizona Center for
Algae Technology and Innovation (AzCATI), located at the Arizona
State University Polytechnic campus in Mesa, Ariz., and the Algae
Test-bed Public-Private Partnership (ATP3).
This research project is the next step toward commercialization
of HEPI's unique bioactive molecules.
The scope of the research project includes:
- Development of a technique to rapidly screen organisms for
bioactivity
- Development of methods for quantification of bioactive
compounds
- Investigate the mode of synthesis for bioactive compounds
- Mass-culturing organisms that produce bioactive compounds for
bovine and canine trials
"In HEPI's years of research we have identified bioactive
molecules with verifiable health benefits for humans and animals
that have attracted quite a lot of attention from potential
licensors," said HEPI CEO Andrew Dahl. "Now is the appropriate time
to commercialize the research, beginning with the cultures and
organisms responsible for creating the bioactive
compounds. "The collaboration with Dr. Thomas Dempster and Dr.
Henri Gerken at AzCATI/ATP3 has yielded a positive outcome from the
very start. We were able to immediately kick off a complex and
aggressive development program that will get our product validated
and market-ready within a reasonable timeframe. The responsiveness
and innovative thinking is an added bonus."
"The research we are doing at AzCATI/ATP3 on HEPI's proprietary
molecules accelerates the process of going to market as we are
refining our knowledge about the bioactives and optimizing culture
growth, allowing for the scale-up to commercial production," said
Dr. Thomas A. Dempster, a Research Associate Professor at ASU's
AzCATI and the ATP3 test-bed site coordinator.
The mass-culture process requires a considerable effort to
determine the most cost-efficient and timely production techniques,
which in the case of the target organisms, may require multi-stage
culturing and extraction.
"We're incorporating real-world financial modeling into the
development process, focusing on capital investment, cost of
operations, life cycle analysis and everything in between," stated
Dahl. "The business model doesn't include any subsidies, grants or
assistance that can distort the ROI and operating margins. We will
certainly take advantage of any program or incentive for which we
qualify during the developmental and scale-up phase, but the
long-term operating model must stand on its own from the very
beginning. That's why HEPI has only pursued high-value nutrition
and health applications over the last few years."
"We're able to look at different culturing techniques,
procedures and outcomes, assist with cost modeling, and suggest
appropriate solutions in a timely and efficient manner," said
Dempster. "We look forward to working with HEPI to determine a
feasible production process that meets all compliance and financial
benchmarks."
"Let's remember that a 'sustainable' business model really means
a profitable business model, because without the prospect of
profitability, it's difficult, if not impossible, to attract
capital, attract top talent, meet operating expenses and fuel any
meaningful growth," added Dahl. "Like any other form of agriculture
or aquaculture, algae production will inevitably mature into a
high-volume, capital-intensive model where process control and
efficiency will make the difference between a solid return and a
hatful of excuses."
About Health
Enhancement Products, Inc.
Health Enhancement Products, Inc. (OTCBB: HEPI) is a
Michigan-based health and wellness company engaged in the
development of natural bioactive compounds for use as dietary
supplements and food ingredients, as well as biologics for
medicinal and pharmaceutical applications in humans and animals.
The Company's scientific efforts are focused on the metabolic
aspects of oxidation and inflammation, with a parallel program to
validate and license products for healthy cholesterol balance. The
newly revised website address is
www.health-enhancement-products.com.
About AzCATI and
ATP3
AzCATI serves as a national test-bed for research, testing, and
commercialization of algae-based products. These include biofuels,
pharmaceuticals, nutraceuticals, and other algae biomass
co-products. AzCATI provides open test and evaluation facilities
for the algae industry and research community. The center can
assess the performance of individual and combined unit operations
across the algal value chain. AzCATI is embedded within ASU's
College of Technology and Innovation and is part of the LightWorks
initiative, supported by ASU's Office of Knowledge Enterprise
Development.
AzCATI leads the ATP3 consortium with support from national labs
and academic and industrial partners including the National
Renewable Energy Laboratory (NREL), Sandia National Laboratories,
Cellana LLC, Touchstone Research Laboratory, Valicor Renewables,
Cal Poly San Luis Obispo, Georgia Institute of Technology,
University of Texas at Austin, and Commercial Algae Management.
ATP3 is funded by a $15 million competitive grant from the
Bioenergy Technologies Office within the US Department of Energy.
The ATP3 collaborative is a network of regional test-beds designed
to empower knowledge creation and dissemination within the algal
research community, accelerate innovation, and support growth of
the nascent algal fuels industry.
Safe Harbor Statement
Except for any historical information, the matters discussed in
this press release contain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. These forward-looking
statements involve risks and uncertainties. A number of factors
could cause actual results to differ from those indicated in the
forward-looking statements, including the timing of completion of a
trial, actual future clinical trial results being different than
the results the company has obtained to date, and the company's
ability to secure funding. Such statements are subject to a number
of assumptions, risks and uncertainties. Readers are cautioned that
such statements are not guarantees of future performance and those
actual results or developments may differ materially from those set
forth in the forward-looking statements. The company undertakes no
obligation to publicly update or revise forward-looking statements,
whether as a result of new information or otherwise.
Zivo Bioscience (QB) (USOTC:ZIVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zivo Bioscience (QB) (USOTC:ZIVO)
Historical Stock Chart
From Apr 2023 to Apr 2024